Free Trial
NASDAQ:CING

Cingulate (CING) Stock Price, News & Analysis

Cingulate logo
$3.83
-0.02 (-0.52%)
(As of 11/4/2024 ET)

About Cingulate Stock (NASDAQ:CING)

Key Stats

Today's Range
$3.80
$3.94
50-Day Range
$3.83
$9.88
52-Week Range
$1.80
$152.40
Volume
43,413 shs
Average Volume
1.20 million shs
Market Capitalization
$11.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Hold

Company Overview

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Cingulate Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
49th Percentile Overall Score

CING MarketRank™: 

Cingulate scored higher than 49% of companies evaluated by MarketBeat, and ranked 625th out of 972 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cingulate has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cingulate has received no research coverage in the past 90 days.

  • Read more about Cingulate's stock forecast and price target.
  • Percentage of Shares Shorted

    1.87% of the float of Cingulate has been sold short.
  • Short Interest Ratio / Days to Cover

    Cingulate has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cingulate has recently increased by 37.28%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cingulate does not currently pay a dividend.

  • Dividend Growth

    Cingulate does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.87% of the float of Cingulate has been sold short.
  • Short Interest Ratio / Days to Cover

    Cingulate has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cingulate has recently increased by 37.28%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Cingulate has a news sentiment score of -0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Cingulate this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for CING on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Cingulate to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cingulate insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $842.00 in company stock.

  • Percentage Held by Insiders

    17.06% of the stock of Cingulate is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    41.31% of the stock of Cingulate is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cingulate's insider trading history.
Receive CING Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter.

CING Stock News Headlines

Why the silent treatment is straight up abusive
Countdown to the biggest trade of my 25 yr career
Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.
See More Headlines

CING Stock Analysis - Frequently Asked Questions

Cingulate's stock was trading at $7.65 on January 1st, 2024. Since then, CING stock has decreased by 49.9% and is now trading at $3.83.
View the best growth stocks for 2024 here
.

Cingulate Inc. (NASDAQ:CING) posted its quarterly earnings results on Tuesday, August, 13th. The company reported ($5.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.64) by $0.17.

Cingulate shares reverse split on the morning of Thursday, November 30th 2023. The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Cingulate (CING) raised $29 million in an initial public offering on Wednesday, December 8th 2021. The company issued 4,166,666 shares at $6.00-$8.00 per share.

Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cingulate investors own include NVIDIA (NVDA), Windtree Therapeutics (WINT), AMC Entertainment (AMC), Sonnet BioTherapeutics (SONN), ARMOUR Residential REIT (ARR), BioCardia (BCDA) and Altamira Therapeutics (CYTO).

Company Calendar

Last Earnings
8/13/2024
Today
11/04/2024
Next Earnings (Estimated)
11/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CING
Fax
N/A
Employees
13
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$8.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+108.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-23,530,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($70.63) per share

Miscellaneous

Free Float
2,525,000
Market Cap
$11.66 million
Optionable
Not Optionable
Beta
-0.89
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:CING) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners